The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Roswell Park Cancer Institute receives “outstanding” distinction from NCI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ROSWELL PARK CANCER INSTITUTE received an “outstanding” distinction from NCI, which renewed its Cancer Center Support Grant and extended its Comprehensive Cancer Center designation, following an in-depth peer review. Roswell Park will receive $19 million with the core grant covering a five-year period.

“With this renewal comes recognition from our peers from cancer centers around the nation of Roswell Park’s excellence in conducting innovative research, distinguished education programs and exemplary patient care,” said RPCI President and CEO Donald Trump.

The panel of peer reviewers from other NCI-designated centers wrote: “Under the exemplary leadership of the Center Director and with the continued involvement of the outstanding and productive Senior Leaders and commitment of the Institution… this established Cancer Center is well positioned to continue its contributions to the national mission to understand and eliminate cancer.”

New York State Governor Andrew Cuomo and Congressman Brian Higgins, along with other state and local leaders, joined Trump for Tuesday’s announcement at the 116-year-old cancer center.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
By Samuel (Tony) Boova, Eda Holl, LaToya Montgomery, Steve Kussick, Nicholas Kigen, Gilbert Olbara, Festus Muigai Njuguna, Terry Vik and Teresa Loile Lotodo
ClinicalTrials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
By Enrique Velazquez-Villarreal
Sponsored

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
By Journal of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account